

Company Announcement no. 24/2015

To: NASDAQ OMX Copenhagen A/S

Hørsholm, Denmark 16 November 2015

Veloxis Pharmaceuticals Announces Financial Calendar for 2016

Veloxis Pharmaceuticals A/S (OMX: VELO) today announced financial calendar for 2016.

9. March, 2016:	Release of Annual Report 2015.
6 April, 2016:	Annual General Meeting.
18 May, 2016:	Interim Report for the 1st Quarter - for the period 1 January to 31 March, 2016.
24 August, 2016:	Interim Report for the 2nd Quarter – for the period 1 January to 30 June, 2016.
16 November, 2016:	Interim Report for the 3rd Quarter – for the period 1 January to 30 September, 2016.

For Investor and media contact:

Bill Polvino
President & CEO
Phone: +1 917 647 9107
Email: wjp@veloxis.com

Johnny Stilou
EVP & CFO
Phone: + 45 30 53 33 64
Email: jst@veloxis.com

About Envarsus® XR

Envarsus® (tacrolimus prolonged-release tablets) has received marketing authorization in the EU for prophylaxis of organ rejection in kidney and liver transplant recipients and in the U.S., branded as Envarsus® XR (tacrolimus extended-release tablets) for prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate release formulations in combination with other immunosuppressants. Envarsus® XR has received orphan drug designation in the U.S. Veloxis plans to commercialize Envarsus® XR in the US through its own sales force and in the EU through its partnership with Chiesi Farmaceutici SpA.

About Veloxis Pharmaceuticals

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis' unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit www.veloxis.com.